Unlearn Announces Leadership Transition to Accelerate Commercial Growth and AI Innovation
Unlearn Announces Leadership Transition to Accelerate Commercial Growth and AI Innovation
Former CEO and Co-Founder Charles Fisher will continue as Chief Scientist; Chief Commercial Officer Steve Herne will transition to CEO
After securing over $130M in funding and achieving multiple regulatory successes, Unlearn today announced changes to its executive leadership to support the commercial expansion of its innovative AI technologies. Effective immediately, CEO and Co‐Founder Charles Fisher will step into the role of Chief Scientist, where he will drive Unlearn’s product and technical innovation. Steve Herne, currently serving as the Chief Commercial Officer, will succeed Fisher as CEO.
"Since founding Unlearn in 2017, our primary focus has been advancing AI research and development to enable smaller, faster clinical trials. We did incredible work, creating the most innovative technologies in the entire clinical trial space. Now, we are entering the next phase—delivering AI products to solve key pain points across clinical development," said Charles Fisher, Ph.D. "Steve’s deep expertise in the pharmaceutical industry and ability to lead teams from research to product delivery make him the ideal person to guide Unlearn through this critical stage of growth."
Founded to advance AI to eliminate trial and error in medicine, Unlearn has grown over the last seven years into a leading AI company in clinical trials. Major global pharmaceutical companies have partnered with Unlearn, leveraging its digital twins of patients to accelerate their clinical research programs.
"Unlearn's dedication to modernizing outdated clinical research processes inspires me every day,” said Herne. “I’m honored to take on the role of CEO and build on the strong foundation Charles has established as he transitions into his new role. I look forward to working alongside Charles and the entire Unlearn team as we enter this exciting new phase of growth.”
For more information about Unlearn, visit: www.unlearn.ai
About Unlearn
Unlearn is a pioneering AI company with a product-driven focus, dedicated to transforming medicine by eliminating trial and error. The Unlearn Platform harnesses the power of digital twins—advanced computational models of patients—to empower pharmaceutical and biotech companies to overcome critical challenges in clinical development.
Alyssa Horowitz
unlearn@pancomm.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240911790223/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk